Inclusion Criteria:

1. Histologically or cytologically confirmed adenocarcinoma of the prostate
2. At least three core biopsies positive for prostate cancer

3. At least one of the following features:

   • PSA >10 ng/ml
   • PSA velocity > 2 ng/ml/year (defined as a rise in PSA of > 2 ng/ml in the preceding12 month period)
   • Gleason score ≥ 7 (4+3)
   • Gleason score 6 if either PSA ≥ 10 ng/ml or PSA velocity ≥ 2 ng/ml/year
4. Serum testosterone > 200 ng/dL
5. Patient and urologist must agree that patient is suitable for prostatectomy
6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1

Exclusion Criteria:

1. Serious or uncontrolled co-existent, non-malignant disease, including active and uncontrolled infection
2. Abnormal liver function
3. Uncontrolled hypertension
4. Clinically significant heart disease
5. Other active malignancy
6. History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug
7. Prior therapy with abiraterone acetate
8. Condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with patient's participation in the study
9. Gleason score ≤ 5 (total)

Note: There are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.